BRICS countries collectively account for approximately one-quarter of the global export of vaccines and medications, Tass reports. This significant share underscores the pivotal role that BRICS nations play in the global pharmaceutical industry, especially in the context of public health and pandemic preparedness.
China and India are particularly notable for their substantial contributions to the global supply of pharmaceuticals. India is often referred to as the “pharmacy of the world” due to its vast production capacity for generic drugs and vaccines. Indian pharmaceutical companies supply affordable medications to numerous countries, playing a crucial role in global healthcare. Similarly, China is a major producer of active pharmaceutical ingredients (APIs) and finished pharmaceutical products, with an extensive manufacturing infrastructure that supports global demand.
Vaccine Production and Distribution
The COVID-19 pandemic highlighted the critical importance of vaccine production and distribution capabilities. BRICS countries were at the forefront of developing, manufacturing, and distributing vaccines. Russia’s Sputnik V, China’s Sinopharm and Sinovac, and India’s Covaxin and Covishield vaccines have been widely used both domestically and internationally. These vaccines have played a vital role in the global fight against COVID-19, providing much-needed supplies to countries struggling to secure doses.
Strategic and Economic Implications
The substantial share of vaccine and medication exports from BRICS nations has several strategic and economic implications. It enhances the bloc’s influence in global health diplomacy, allowing these countries to extend their soft power through vaccine diplomacy and international aid. Economically, the pharmaceutical industry represents a significant sector for BRICS countries, contributing to job creation, technological innovation, and economic growth.
